ABIONYX Pharma
ISIN: FR0012616852 | Ticker: ABNX | LEI: 969500785J7VIC5YPC96
Country: France
ABIONYX Pharma is a new-generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones
Thanks to its partners in research, medicine, its bioproduct suppliers and its shareholders, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
Bât. D2 33-43 Avenue Georges Pompidou, 31130 Balma – France
| Line item in (eur) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 10,288,000.00 | N/A | 21,832,000.00 | 15,823,000.00 |
| Noncurrent Assets | N/A | 255,000.00 | N/A | 8,821,000.00 | 8,251,000.00 |
| Property Plant And Equipment | N/A | 91,000.00 | N/A | 340,000.00 | 373,000.00 |
| Goodwill | N/A | N/A | N/A | 5,377,000.00 | 5,377,000.00 |
| Other Noncurrent Assets | N/A | 95,000.00 | N/A | 300,000.00 | 240,000.00 |
| Current Assets | N/A | 10,033,000.00 | N/A | 13,011,000.00 | 7,572,000.00 |
| Inventories | N/A | N/A | N/A | 177,000.00 | 147,000.00 |
| Cash and cash equivalents | N/A | 9,154,000.00 | N/A | 7,935,000.00 | 4,046,000.00 |
| Other Current Assets | N/A | 879,000.00 | N/A | 3,566,000.00 | 2,082,000.00 |
| Equity And Liabilities | N/A | 10,288,000.00 | N/A | 21,832,000.00 | 15,823,000.00 |
| Equity | 6,666,000.00 | 6,629,000.00 | 6,629,000.00 | 10,677,000.00 | 7,169,000.00 |
| Issued Capital | N/A | 1,232,000.00 | N/A | 1,396,000.00 | 1,418,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | N/A | -5,822,000.00 | -4,206,000.00 |
| Share Premium | N/A | 170,322,000.00 | N/A | 179,214,000.00 | 8,599,000.00 |
| Noncurrent Liabilities | N/A | 61,000.00 | N/A | 4,408,000.00 | 3,560,000.00 |
| Longterm Borrowings | N/A | N/A | N/A | 1,653,000.00 | 1,415,000.00 |
| Current Liabilities | N/A | 3,598,000.00 | N/A | 6,747,000.00 | 5,094,000.00 |
| Current Provisions | N/A | 931,000.00 | N/A | 942,000.00 | 931,000.00 |
| Current Provisions For Employee Benefits | N/A | N/A | N/A | 504,000.00 | 417,000.00 |
| Trade And Other Current Payables | N/A | 2,411,000.00 | N/A | 2,705,000.00 | 1,853,000.00 |
| Other Current Financial Liabilities | N/A | N/A | N/A | 653,000.00 | 491,000.00 |
| Other Current Nonfinancial Liabilities | N/A | N/A | N/A | 2,046,000.00 | 1,440,000.00 |
| Other Current Liabilities | N/A | 232,000.00 | N/A | 2,046,000.00 | N/A |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | N/A | 675,000.00 | 5,252,000.00 |
| Other Gains Losses | N/A | -37,000.00 | 23,000.00 |
| Profit Loss From Operating Activities | -2,968,000.00 | -5,952,000.00 | -4,109,000.00 |
| Finance Income | 1,195,000.00 | 307,000.00 | 165,000.00 |
| Finance Costs | 113,000.00 | 177,000.00 | 262,000.00 |
| Profit (loss) | -1,886,000.00 | -5,822,000.00 | -4,206,000.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | -1,886,000.00 | -5,822,000.00 | -4,206,000.00 |
| Adjustments For Provisions | -39,000.00 | -49,000.00 | 119,000.00 |
| Adjustments For Sharebased Payments | 98,000.00 | 815,000.00 | 506,000.00 |
| Other Adjustments For Noncash Items | -23,000.00 | -10,000.00 | 0.00 |
| Cash Flows From Used In Operations | -2,729,000.00 | -4,948,000.00 | -3,456,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | -599,000.00 | -6,692,000.00 | -3,359,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 23,000.00 | 3,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 103,000.00 | 166,000.00 | 165,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 0.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 45,000.00 | 0.00 | 10,000.00 |
| Cash Flows From Used In Investing Activities | -125,000.00 | 1,338,000.00 | -175,000.00 |
| Proceeds From Issuing Shares | 1,836,000.00 | 4,056,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 19,000.00 | 236,000.00 |
| Cash Flows From Used In Financing Activities | 1,547,000.00 | 3,972,000.00 | -194,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 823,000.00 | -1,382,000.00 | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -1,382,000.00 | -3,728,000.00 |
| Cash and cash equivalents | 9,154,000.00 | 7,935,000.00 | 4,046,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 28.02.23 | None | Other | Buy | EUR 0.00 |
FR0012616852
LEI969500785J7VIC5YPC96
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.